Theratechnologies to Announce Financial Results for Its First Quarter Fiscal 2021GlobeNewsWire • 04/12/21
Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer TypesGlobeNewsWire • 04/10/21
Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline AssetsGlobeNewsWire • 03/29/21
Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid TumorsGlobeNewsWire • 03/24/21
Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver InflammationGlobeNewsWire • 03/20/21
Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021GlobeNewsWire • 03/10/21
Theratechnologies Inc. (THTX) CEO Paul Levesque on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/28/21
Theratechnologies to Present at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewsWire • 02/25/21
Theratechnologies Announces Fourth Quarter and Fiscal Year 2020 Financial ResultsGlobeNewsWire • 02/25/21
Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020GlobeNewsWire • 02/11/21
Theratechnologies' Peptide Conjugate Candidate For Solid Tumor Nabs Priority Review Tag In US, Shares RallyBenzinga • 02/04/21
Theratechnologies' Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing CancersGlobeNewsWire • 02/04/21
Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment OptionGlobeNewsWire • 01/19/21
Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor ConferenceGlobeNewsWire • 01/14/21
Theratechnologies Announces US$40 Million Bought-Deal Public Offering of UnitsGlobeNewsWire • 01/12/21
Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D ActivitiesGlobeNewsWire • 01/07/21
Theratechnologies Announces New Findings for its Lead Investigational Compound TH1902 for the Treatment of Several Additional CancersGlobeNewsWire • 12/08/20
Theratechnologies to Present at the Piper Sandler Virtual Healthcare ConferenceGlobeNewsWire • 11/23/20
Theratechnologies Announces Data From Oral Presentation at AASLD Showing How Tesamorelin Can Reduce Fibrosis and NASHGlobeNewsWire • 11/16/20
Theratechnologies Announces that Data on the Mechanism of Effect of Tesamorelin in NAFLD will be Presented at The Liver Meeting® 2020GlobeNewsWire • 11/06/20
Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020GlobeNewsWire • 10/22/20
Theratechnologies Confirms Issuance of U.S. Patent Covering the Use of Tesamorelin in the Treatment of Individuals Suffering From NAFLD/NASHGlobeNewsWire • 10/13/20